SHORT-TERM (1 WEEK) INGESTION OF WHEAT AMYLATE INHIBITOR IN OBESITY AND DIABETES

短期（1 周）摄入小麦淀粉酯抑制剂治疗肥胖和糖尿病

• 批准号: 6117444
• 负责人: E DIMAGNO
• 金额: $ 2.01万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117444
• 关键词: amylases; blood glucose; carbohydrate metabolism; clinical research; diabetes mellitus; diabetes mellitus therapy; enzyme inhibitors; gastrointestinal function; human subject; human therapy evaluation; obesity

The aim of this protocol was to determine in diabetics the effect of giving wheat amylase inhibitor for 1 week on blood glucose and gastrointestinal hormones. Six diabetics were fed a standard weight maintenance diet for 3 weeks. During week I, usually therapy for diabetes mellitus was continued. Wheat amylase inhibitors and diabetic medications were withheld during the third week. On days 7, 14, and 21, blood was drawn before and every 1/2 hour for 4 hours postprandially for blood glucose, c-peptide and HPP. During week II (compared to week III), the delta blood glucose (area under the curve) and concentrations of c-peptide and HPP were lower in response to dinner. One patient developed loose stools on wheat amylase inhibitors that improved by day 6. Wheat amylase inhibitor lowers blood glucose in diabetes mellitus, more so with larger meals. Wheat amylase inhibitor is potentially useful and safe therapy for diabetes mellitus; however, long-term studies in more diabetics are needed to confirm the efficacy and safety of the wheat amylase inhibitor.

该方案的目的是确定糖尿病患者服用小麦淀粉酶抑制剂1周对血糖和胃肠激素的影响。6名糖尿病患者按标准体重维持饮食喂养3周。在第一周，通常继续糖尿病的治疗。在第三周，小麦淀粉酶抑制剂和糖尿病药物被扣留。于第7、14、21天分别于餐前及餐后4h每隔1/2小时采血一次，测定血糖、C-肽、HPP。在第二周(与第三周相比)，增量血糖(曲线下面积)以及C-肽和HPP浓度对晚餐的反应较低。一名患者服用小麦淀粉酶抑制剂后出现大便松弛，在第6天有所改善。小麦淀粉酶抑制剂可降低糖尿病患者的血糖，尤其是饮食较多的患者。小麦淀粉酶抑制剂对糖尿病有潜在的有效和安全的治疗作用；然而，还需要在更多的糖尿病患者中进行长期研究来证实小麦淀粉酶抑制剂的有效性和安全性。